Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysisArticle Published on 2022-10-012022-11-15 Journal: Joint bone spine [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome addition Antibody Response biologic Cohort cohort study conducted coronavirus COVID-19 COVID-19 pandemic disease evaluated identify IgG antibody immune-mediated diseases impair individuals Inflammatory Inflammatory rheumatic diseases IQR leflunomide less management median age Meta-analysis methotrexate observational study Older participant Patient performed Prevalence reported rheumatic disease rituximab robust Sample size SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV2 vaccination second vaccination seroconversion rate seroconverted serological response significantly Spike protein suggested targeted therapy Therapies therapy treated two-dose regimen vaccination Vaccine were measured [DOI] 10.1016/j.jbspin.2022.105380 PMC 바로가기
Saliva as Blood Alternative in Therapeutic Monitoring of Teriflunomide-Development and Validation of the Novel Analytical MethodArticle Published on 2022-08-232022-11-16 Journal: International Journal of Molecular Sciences [Category] SARS, 치료기술, [키워드] analyzed biologically active metabolite Blood can be used characterized collected Concentration correlation criteria dosage drug Effectiveness evaluated Good LC-MS/MS leflunomide life-threatening linear monitoring Non-invasive novel pharmacokinetic plasma quantification reduce regimen robust Saliva salivary SARS-CoV-2 pandemic Side effect stimulated Swab Teriflunomide therapeutic therapeutic drug Therapeutic Drug Monitoring validation Variability was obtained [DOI] 10.3390/ijms23179544 PMC 바로가기
Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study류마티스 관절염 환자에서 메토트렉세이트를 배경으로 추가적인 레플루노마이드 또는 타크롤리무스와 TNF 억제제의 감염 위험: 인구 기반 코호트 연구Article Published on 2022-08-012023-06-01 Journal: Seminars in arthritis and rheumatism [Category] 대상포진, 두창, 수두, 홍역, [키워드] Infection leflunomide rheumatoid arthritis tacrolimus TNF inhibitor [DOI] 10.1016/j.semarthrit.2022.152019
COVID-19 among patients with giant cell arteritis: a single-centre observational study from SloveniaReview Published on 2022-08-012023-07-08 Journal: Clinical Rheumatology [Category] COVID19(2023년), [키워드] COVID-19 giant cell arteritis Glucocorticoids leflunomide outcome assessment [DOI] 10.1007/s10067-022-06157-4 PMC 바로가기 [Article Type] Review
Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis전신성 홍반성 루푸스 및 류마티스 관절염에서 SARS-CoV-2 특이 항체의 혈청유병률 및 백신 접종 관련 이상반응Article Published on 2022-06-012022-09-12 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] addition adverse effect adverse event Analysis antibody autoantibody CMIA Complete coronavirus 2 Coronavirus disease 2019 COVID-19 COVID-19 vaccine effective HCs healthy control IgG and IgM IgG antibody IgM antibody immunoassay immunogenic inactivated indicated leflunomide Microparticle no significant difference pandemic of COVID-19 Patient patients Prevent RA Rash recruited regimen respiratory reveal rheumatoid arthritis Safe SARS-CoV-2 SARS-CoV-2-specific antibody Seroprevalence SLE SLE patients systemic lupus erythematosus the disease vaccination Vero cells [DOI] 10.1016/j.biopha.2022.112997 PMC 바로가기 [Article Type] Article
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases면역 매개 염증성 류마티스 질환 환자에서 SARS-CoV-2에 대한 mRNA 백신에 대한 면역 반응Article Published on 2022-01-012022-09-12 Journal: RMD Open [Category] SARS, 진단, [키워드] abatacept age Autoimmune Autoimmune diseases B-cell CD4 CD8 Cellular immune response cellular response Cellular responses correlated COVID-19 cumulative deleterious effects demonstrated depleting dose drug Effect Efficacy elicited Gender glucocorticoid healthy controls humoral humoral responses identify immune response immune system immune system diseases Immune-mediated Immunosuppression immunotherapies infections Inflammatory introduced investigated leflunomide methotrexate mRNA mRNA vaccine mRNA vaccines naïve Patient patients with SARS-CoV-2 phase III trial preserved receiving reduce reduced responders response rheumatic disease rituximab SARS-CoV-2 SARS-CoV-2 vaccine selected Seroconversion seroconversion rate T-cell immune response T-lymphocyte subsets the vaccine Therapies therapy titre treated two-dose regimen vaccination Vaccine were excluded [DOI] 10.1136/rmdopen-2021-001898 PMC 바로가기 [Article Type] Article
Treatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical TrialLeflunomide로 장기간의 증상 후 바이러스 방출이 있는 코로나바이러스 질병 2019 환자의 치료: 단일 센터 무작위 통제 임상 시험Randomized Controlled Trial Published on 2021-12-062022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 치료제, [키워드] addition administration adult COVID-19 patient adverse events approved assigned benefit Chain Reaction clinical combined treatment Complete conducted confidence interval Controlled coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 patient Efficacy and safety evaluate hazard ratio Hospital stay Hospitalized inhibitor interferon Interferon alpha interferon alpha 2a interquartile range IQR leflunomide median nebulized once daily Open-label open-label trial Patient patients treated PCR PCR positivity polymerase chain polymerase chain reaction primary endpoint Prolonged Randomized Randomly receive recipient SARS-CoV-2 shedding the patient treat Trial viral shedding [DOI] 10.1093/cid/ciaa1417 PMC 바로가기 [Article Type] Randomized Controlled Trial
Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19Research article Published on 2021-09-112022-10-05 Journal: Current Research in Pharmacology and Drug Discovery [Category] 신약개발, 치료법, 치료제, [키워드] activity acute respiratory syndrome Analysis Anti-COVID-19/Anti-SARS-CoV-2 drug anti-SARS-CoV-2 antiviral action binding binding affinity binding interaction binding pocket carried caused Computational molecular docking Coronaviral-2 RNA-dependent RNA polymerase (RdRp) coronavirus coronavirus disease COVID-19 COVID-19 cytokine storm docking drug candidate Drug discovery effective evaluate GS-441524 Health hypothetical inhibit inhibitory inhibitory activity leflunomide Ligand lower binding energy mechanism metabolite molecular docking pandemic Particle pharmacological problem Protein RdRP Remdesivir/GS-441524 Replication reported Research RNA RNA-dependent RNA polymerase SARS-CoV-2 SARS-CoV-2 strain server significantly Support Teriflunomide the SARS-CoV-2 therapy Treatment Trial undergo viral replication were used [DOI] 10.1016/j.crphar.2021.100055 [Article Type] Research article
Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trialarticle Published on 2021-08-152024-09-02 Journal: Renal failure [Category] 대상포진, [키워드] Disease progression Glucocorticoids IgA nephropathy leflunomide Proteinuria [DOI] 10.1080/0886022X.2021.1963775 PMC 바로가기 [Article Type] article
Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot StudyPharmacology Published on 2021-07-022022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute respiratory syndrome age assigned clearance rate coronavirus coronavirus disease Course COVID-19 death discharge rate enrolled hospital discharge rate Hospitalized IMPROVE IQR large sample leflunomide observation Patient patients pilot study Pneumonia positive Primary outcome Randomized controlled trial receive receiving refractory reported Safety SARS-CoV-2 SARS-CoV-2 clearance SARS-CoV-2 viral severe adverse event standard care Standard of care the median the SARS-CoV-2 Tolerability Treatment [DOI] 10.3389/fphar.2021.581833 PMC 바로가기 [Article Type] Pharmacology